Most trials open at Rush University Medical Center for CNS tumors are for patients 18 years of age and older, though there may be exceptions. Trials will also generally require patients to be healthy enough to undergo the proposed treatment being examined in the trial. Details about trial eligibility can be discussed with your Rush provider, though some information is also linked to here.
ROADS: GammaTile Brachytherapy vs Postoperative SRS for Resected Brain Metastases
GBM
NRG-BN010: Phase II Study of Combination Tocilizumab, Atezolizumab, and fSRS in Recurrent GBM
Meningioma
NRG-BN003: Observation vs Radiation for Completely Resected Grade 2 Meningioma
A071401: Phase II Trial of SMO/AKT/NF2/CDK Inhibitors in Progressive Meningiomas with SMO/AKT/NF2/CDK Pathway Mutations
Other
---
Spine
MTRON: Multicenter Prospective Registry for the Management and Outcome of Metastatic Spine Tumors
Clinical Trials Set to Open Soon
Brain Metastases
JLF-200: Neoantigen Therapeutic Cancer Vaccine Study
NRG-BN013: Phase III Trial of Single Fraction SRS vs Fractionated SRS for Intact Brain Metastases
GBM
A072201: Radnomized Phase II Trial of Anti-Lag-3 and Anti-PD-1 Blockade vs SOC in Recurrent GBM
GESTALT: Feasibility Study of Resection and GammaTile Followed by Concomitant EBRT and TMZ and Adjuvant TMZ in Newly Diagnosed GBM
Meningioma
---
Other
---
Spine
---
Clinical Trials Closed at RUMC
Brain Metastases
A071701: Genomically-Guided Treatment Trial in Brain Metastases
NRG-BN009: Phase III Trial of Salvage SRS vs SRS with HA-WBRT for Brain Metastasis Relapse (>/= 4 brain metastases/year)
NRG-CC003: Randomized Phase II/III Trial of PCI with or without HA-WBRT for SCLC
NRG-CC009: Phase III Trial of SRS vs HA-WBRT for 10 or Fewer Brain Metastases in SCLC
GBM
A071102: A Phase II/III Randomized trial of Veliparib or Placebo with Adjuvant TMZ in Newly Diagnosed GBM with MGMT Methylation
A071101: Phase II Randomized Trail Comparing HSPPC-96 Vaccine Given with Bevacizumab vs Bevacizumab Alone for Resectable Recurrent GBM
CNS-201: Open-Label Study of IV Berubicin in Recurrent GBM After Failure of Standard FLT
Enzasturin: Trial for Newly Diagnosed GBM Patients with Biomarker DGM1
TRIDENT / EF-32: A Phase III Randomized, open-label study of Optune (TTFields) concomitant with radiation therapy and temozolomide for the treatment of newly diagnosed glioblastoma
Meningioma
---
Other
A071601: Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas